EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of “Moderate Buy” from Analysts

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPTGet Rating) have been assigned a consensus rating of “Moderate Buy” from the five research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $27.00.

A number of equities research analysts have recently commented on the company. HC Wainwright lifted their price objective on EyePoint Pharmaceuticals from $24.00 to $25.00 in a research report on Thursday, August 4th. StockNews.com raised EyePoint Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, September 13th. Finally, Chardan Capital assumed coverage on EyePoint Pharmaceuticals in a research report on Thursday, July 7th. They set a “buy” rating and a $21.00 price target for the company.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of EyePoint Pharmaceuticals in the first quarter worth about $30,000. Amalgamated Bank acquired a new position in shares of EyePoint Pharmaceuticals in the first quarter worth about $31,000. Point72 Hong Kong Ltd acquired a new stake in EyePoint Pharmaceuticals during the fourth quarter valued at approximately $36,000. Cubist Systematic Strategies LLC raised its stake in EyePoint Pharmaceuticals by 46.6% during the second quarter. Cubist Systematic Strategies LLC now owns 6,600 shares of the company’s stock valued at $52,000 after buying an additional 2,099 shares in the last quarter. Finally, Royal Bank of Canada raised its stake in EyePoint Pharmaceuticals by 31.9% during the first quarter. Royal Bank of Canada now owns 7,934 shares of the company’s stock valued at $97,000 after buying an additional 1,918 shares in the last quarter. Hedge funds and other institutional investors own 88.65% of the company’s stock.

EyePoint Pharmaceuticals Price Performance

Shares of NASDAQ:EYPT opened at $7.78 on Tuesday. The company has a market cap of $265.08 million, a P/E ratio of -3.46 and a beta of 1.21. The company has a quick ratio of 6.07, a current ratio of 6.17 and a debt-to-equity ratio of 0.19. EyePoint Pharmaceuticals has a 52 week low of $6.99 and a 52 week high of $21.50. The business has a fifty day simple moving average of $9.79 and a 200-day simple moving average of $10.24.

About EyePoint Pharmaceuticals

(Get Rating)

EyePoint Pharmaceuticals, Inc, a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery.

Further Reading

Receive News & Ratings for EyePoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EyePoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.